Portal de Periódicos da CAPES

Development of an anti‐BAG3 humanized antibody for treatment of pancreatic cancer

2019; Elsevier BV; Volume: 13; Issue: 6 Linguagem: Inglês

10.1002/1878-0261.12492

1878-0261

Anna Basile, Margot De Marco, Michelina Festa, Antonia Falco, Vittoria Iorio, Luana Guerriero, Daniela Eletto, Domenica Rea, Claudio Arra, Alessia Lamolinara, Patrizia Ballerini, Verena Damiani, Alessandra Rosati, Gianluca Sala, Maria Caterina Turco, Liberato Marzullo, Vincenzo De Laurenzi,

Pancreatic and Hepatic Oncology Research

We have previously shown that secreted BAG3 is a potential target for the treatment of pancreatic ductal adenocarcinoma and that pancreatic tumor growth and metastatic dissemination can be reduced by treatment with an anti-BAG3 murine antibody. Here, we used complementarity-determining region (CDR) grafting to generate a humanized version of the anti-BAG3 antibody that may be further developed for possible clinical use. We show that the humanized anti-BAG3 antibody, named BAG3-H2L4, abrogates BAG3 binding to macrophages and subsequent release of IL-6. Furthermore, it specifically localizes into tumor tissues and significantly inhibits the growth of Mia PaCa-2 pancreatic cancer cell xenografts. We propose BAG3-H2L4 antibody as a potential clinical candidate for BAG3-targeted therapy in pancreatic cancer.